Top

Ernest Hawk, M.D., M.P.H.

Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences

About Dr. Hawk

Ernest Hawk, M.D., MPH, is vice president and head of the division of Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center and holds the T. Boone Pickens Distinguished Chair for Early Prevention of Cancer. Additional responsibilities include leadership of the Duncan Family Institute for Cancer Prevention and Risk Assessment and co-leadership of MD Anderson’s Cancer Prevention and Control Platform which advances community health promotion and cancer control through evidence-based public policy, public and professional education, and community-based service implementation and dissemination.

A native of Detroit, Michigan, Dr. Hawk earned his medical degree from Wayne State University and his Master of Public Health degree at Johns Hopkins University. He completed an internal medicine internship and residency at Emory University, a medical oncology clinical fellowship at the University of California, San Francisco, and a cancer prevention fellowship at the National Cancer Institute (NCI).

Prior to his appointment at MD Anderson in December 2007, Dr. Hawk held several positions at the NCI in Bethesda, MD. He most recently served as director of the Office of Centers, Training and Resources, responsible for the NCI’s cancer centers program, a major translational science program (i.e., the SPORE program), the NCI’s extramural training enterprise, and its extramural disparities portfolio. His prior NCI posts included chief and medical officer of the Gastrointestinal and Other Cancers Research Group, medical officer in the Chemoprevention Branch, and chair of the Translational Research Working Group.

Dr. Hawk has been involved in a wide range of preclinical and clinical chemoprevention research, including developmental studies of nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, and preventive agent combinations in high-risk cohorts. Interests include the improvement of minority and medically underserved populations’ participation in clinical research, future applications of multi-cancer early detection tests, and the integration of risk assessment, behavioral science, and preventive strategies developed through sequential clinical trials for application in clinical or public health settings. He has published more than 180 scientific articles and book chapters, edited three books, serves as an editor of Holland & Frei’s Cancer Medicine (10^th edition), and serves as the senior deputy editor for Cancer Prevention Research, and on the editorial board of Cancer Medicine.

Dr. Hawk can be reached at 713-792-3900 or through his Office Manager, Wendy McDaniel at 713-745-0490 or via email (wcmcdaniel@mdanderson.org)

Meet Ernest Hawk, M.D.

In the News

Close-up view of roofing tiles containing asbestos fibers

Asbestos exposure and cancer: 8 things to know

Illustration to show blood detection through magnified glass.

What are multi-cancer early detection (MCED) tests, and should you get one?

Glass jar containing several types of sweeteners in packets

Artificial sweeteners and cancer: 7 things to know 

Illustration of teensy person and doctor in lab coat examining oversized lung X-ray with giant magnifying glass showing chemical symbol for radon

Radon exposure and lung cancer: 11 things to know

Cancerwise Blog Post: Learn how MD Anderson's Cancer Moon Shots Program is working to end cancer through cancer prevention

How MD Anderson’s Moon Shots Program is working to end cancer through prevention

Present Title & Affiliation

Primary Appointment

Co-Director, Department of CCSG, Community Outreach and Engagement Component, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Boone Pickens Distinguished Chair for Early Prevention of Cancer, Department of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Director, Duncan Family Institute for Cancer Prevention and Risk Assessment, Department of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Vice President, Department of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Division Head, Department of Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Director, Department of CCSG, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Division of Cancer Prevention & Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Cancer Prevention and Control

Translational Research

Molecular Intersections between Cancer and Other Diseases

Education & Training

Degree-Granting Education

1994	Johns Hopkins University School of Hygiene & Public Health, Baltimore, MD, US, Epidemiology/Biostatistics, Masters of Public Health
1985	Wayne State University School of Medicine, Detroit, MI, US, Medicine, Medical Doctorate
1981	Wayne State University, Detroit, MI, US, Biological Sciences, Bachelor of Science

Postgraduate Training

2025-2025	Ethics Training for Special Government Employee, Department of Health & Human Services, Washington, D.C, District of Columbia
2024-2024	Certified Tobacco Treatment Specialist, Tobacco Treatment Training Certificate Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
2008-2009	Advanced Professional Training, Faculty Academic Leadership, The University of Texas MD Anderson Cancer Center, Houston, TX
1993-1996	Research Fellowship, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD
1991-1993	Clinical Fellowship, Medical Oncology, University Of California, San Francisco
1985-1988	Clinical Internship and Residency, Internal Medicine, Emory University Affiliated Hospitals, Atlanta, GA

Board Certifications

2013	American Board of Internal Medicine - Medical Oncology
2003	American Board of Internal Medicine - Recertification in Medical Oncology
1993	American Board of Internal Medicine - Diplomate in Medical Oncology
1988	American Board of Internal Medicine - Diplomate in Internal Medicine
1986	National Board of Medical Examiners - Diplomate

Experience & Service

Academic Appointments

Director, Department of Office of the Director, National Cancer Institute, Bethesda, MD, 2004 - 2007

Chief & Medical Officer, Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1999 - 2004

Medical Officer, Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1997 - 1999

Special Expert (Translational Cancer Prevention), Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1996 - 1997

Administrative Appointments/Responsibilities

Associate Director, Department of CCSG, Community Outreach and Engagement Component, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2024

Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2016

Co-Director, Department of Moonshot Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2024

Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011

Associate Director, Department of CCSG, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present

Department Chair ad interim, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2009

Division Head, Department of Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present

Other Appointments/Responsibilities

Ad Hoc Advisory Consultant, CCSG P30 grant renewal, Northwestern University, Chicago, IL, 2025 - Present

Consultant (Unpaid), Shield™ Blood Test for Colorectal Cancer (CRC) Screening, Guardant Health, Palo Alto, CA, 2024

Extramural Reviewer, Division Head Appointment Review, DKFZ Hector Cancer Institute at University Medicine Mannheim, Heidelberg, 2024

Member (offered), Expert Review Panel, Cancer Research UK, London, 2024

Member, Scientific Advisory Board, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

Member, External Scientific Review Committee for the DKFZ (German National Cancer Research Center), Helmholz Foundation, Heidelberg, 2024 - 2025

External Advisory Board, U54 SPORE on the Biology of Colorectal Cancer Disparities, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, 2024 - Present

Member, Innovation Council, Prevent Cancer Foundation, Alexandria, VA, 2023 - Present

Co-chair, External Scientific Advisory Board, Mayo Clinic, Rochester, MN, 2023 - Present

Member, Task Force to Advance the Care of Sexual and Gender Minority Cancer Patients, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present

Consultant (paid to MD Anderson), Multi-cancer early detection device development, Exact Sciences, Madison, WI, 2022 - Present

Member, External Advisory Board, Medical University of South Carolina, Charleston, SC, 2021 - Present

Member, External Advisory Board, Oregon Health Sciences University, Portland, OR, 2021 - Present

Member, External Advisory Board for the Virginia Survivor Cohort, Virginia Commonwealth University, Richmond, VA, 2020 - 2021

At-Large Member, Women's Leadership Network Steering Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023

Member, Lung Moonshot Executive Steering Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Member, External Advisory Board, University of Alabama at Birmingham, Birmingham, AL, 2020 - Present

Champion, Diversity, Equity, and Inclusion, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023

Chair, External Scientific Advisory Board, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, 2020

Extramural advisory, Search Committee for the Director of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 2019 - 2020

Member, External Advisory Board, Virginia Commonwealth University, Richmond, VA, 2019 - 2023

Member, Strategic Planning Working Group (ad hoc), National Cancer Institute, Bethesda, MD, 2019

Member, Advisory Group on Multicancer Early Detection Tests - Potential Development Strategies and Uses, Mayo Clinic, Rochester, MN, 2019 - 2021

Member, Howard-Hopkins Partnership Steering Committee (PSC), Sidney Kimmel CCC & Howard University Cancer Center, Baltimore, MD, 2019 - 2020

Member, External Advisory Board, Rutgers University, New Brunswick, NJ, 2019 - Present

Member, Clinical and Translational Research Advisory Committee (CTAC), National Cancer Institute, Bethesda, MD, 2019 - 2024

Chair, Community Outreach and Engagement External Advisory Board, Mayo Clinic Cancer Center, Rochester, MN, 2019

Co-Chair, Internal Advisory Committee, University of Puerto Rico and the University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present

Member (ad hoc), External Advisory Committee, University of Wisconsin-Madison, Madison, WI, 2018 - 2020

Member, NCI Ideas Workshop, National Cancer Institute, Bethesda, MD, 2018 - 2019

Member, Physician Scientist Oncology Training Program - External Advisory Committee, UT Southwestern Medical Center, Dallas, TX, 2018 - 2020

Member, External Scientific Advisory Committee, Albert Einstein Cancer Center, Bronx, NY, 2018 - 2020

Member, External Advisory Panel (ad hoc), Fred Hutchinson Cancer Research Center, Seattle, WA, 2017

Member, External Advisory Board, Johns Hopkins University, Baltimore, MD, 2017 - Present

Co-Chair, Cancer Prevention Steering Committee, National Cancer Institute, Bethesda, MD, 2017 - 2023

Member, External Advisory Panel, University of New Mexico, Albuquerque, NM, 2017 - 2024

Participant, Biden's Cancer Moonshot initiative, Blue Ribbon Panel Working Group on Precision, Prevention and Early Detection, Washington, DC, 2016 - 2018

Member, External Advisory Board, University of Nebraska Medical Center, Omaha, NE, 2015 - Present

Member, Board of Directors, MD Anderson Physicians Network (MDAPN), Houston, TX, 2015 - 2016

Member, Gastric and Esophageal Cancers Working Group, National Cancer Institute, Bethesda, MD, 2015 - 2018

Member, Board of Directors, CATCH Global Foundation, Austin, TX, 2015 - 2024

Invited Member, Models Across Miles - Partnership Strategies for Regional Health Improvement, The University of Texas System, Austin, Texas, 2014

Member, Cancer Center Director Search Committee, University of Texas - Austin, Austin, TX, 2014 - 2015

Member, Advisory Board, Pozen Pharmaceutical Development Company, Raleigh, NC, 2013 - 2014

Member, Process of Care Research Branch (PCRB) Working Group, National Cancer Institute, Rockville, MD, 2012 - 2017

Member, External Advisory Board, The University of Texas - Southwestern, Dallas, TX, 2011 - Present

Consultant, External Cancer Research Review and Center Planning, University of Illinois - Chicago, Chicago, IL, 2010 - 2013

Consultant, Special Government Employee (SGE), Oncologic Drugs Advisory Committee (ODAC), Food and Drug Administration, Silver Springs, MD, 2010 - 2015

Consultant and committee member, Multilevel Interventions Across the Cancer Care Continuum Committee, National Cancer Institute, Rockville, MD, 2010 - 2013

Moderator, Translational Science Meeting, National Cancer Institute, Vienna, VA, 2009

Member, Editorial Advisory Board, Prevention Magazine, Emmaus, PA, 2009 - 2014

Member, Process to Accelerate Translational Science Working Group (PATS WG), National Cancer Institute, Bethesda, MD, 2009 - 2013

Member, CCSG External Advisory Board (ad hoc), University of Arizona Cancer Center, Tucson, AZ, 2009

Member, Scientific Steering Committee, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Oxford, 2009 - 2013

Member, External Advisory Board, Roswell Park Cancer Institute, Buffalo, NY, 2008 - Present

Member, External Advisory Board, University of Utah, Salt Lake City, UT, 2008 - Present

Member, External Scientific Advisory Board, Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, OH, 2008 - 2017

Panelist, Translational Science, Indiana Health Industry Forum - Oncology Summit, Indianapolis, IN, 2008

Member, External Advisory Board, Mayo Clinic, Rochester, MN, 2008 - Present

Member, Extramural Scientific Advisory Committee, Harris County Hospital and University National Children's Study, Houston, TX, 2008 - 2013

Special Advisor on Cancer Prevention, Cancer Institute of New Jersey, Somerset, NJ, 2008

Member, External Advisory Board, University of Kansas, Kansas City, KS, 2008 - Present

Advisor, National Cancer Prevention Initiative, National Cancer Institute of Canada and Canadian Cancer Society, Toronto, Ontario, 2006 - 2008

Executive Secretary, National Cancer Advisory Board - Cancer Centers Subcommittee, National Cancer Institute, Bethesda, MD, 2005 - 2007

Co-chair, Translational Research Working Group, National Cancer Institute, Bethesda, MD, 2005 - 2007

Member, Executive Committee, National Cancer Institute, Bethesda, MD, 2004 - 2007

Co-Leader, Scientific Advances Symposium Planning Project Team, National Cancer Institute, Bethesda, MD, 2002 - 2003

Facilitator, SPORE (P50) Program - Colorectal Cancer Research Program, National Cancer Institute, Bethesda, MD, 2002 - 2004

NCI Representative, Secretary's Initiative on Colorectal Cancer, Department of Health and Human Services, Bethesda, MD, 2002 - 2003

Executive Director, Stomach and Esophageal Cancer Progress Review Group, National Cancer Institute, Bethesda, MD, 2001 - 2005

Member, Flat Adenoma and ACF Project Team, National Cancer Institute, Bethesda, MD, 2001 - 2002

Member, Cancer Prevention Scientific Education Committee, National Cancer Institute, Bethesda, MD, 2000 - 2001

Member, Prevention of Languishing Studies Project Team, National Cancer Institute, Bethesda, MD, 2000 - 2001

Member, Clinical Trials Project Team, National Cancer Institute, Bethesda, MD, 2000 - 2001

Co-Chair, Working Group on Barrett's-associated Cancer, National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2000 - 2002

Member, Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Scientific Coordination & Oversight Panel, National Cancer Institute, Bethesda, MD, 1999 - 2005

Member, Coordinating Unit, National Cancer Institute, Bethesda, MD, 1999 - 2005

Member, Committee on Public Educational Materials for Cancer Prevention, National Cancer Institute, Bethesda, MD, 1997 - 1998

Ad Hoc Member, Community Clinical Oncology Program - Prevention & Control Concept & Protocol Review Committees, National Cancer Institute, Bethesda, MD, 1996 - 2005

NCI Divisional Representative, International Common Toxicity Criteria Revision Committee (Version 2.0), National Cancer Institute, Bethesda, MD, 1996 - 1997

Member and Chair, Source Evaluation Groups for Phase II Chemoprevention Trials, National Cancer Institute, Bethesda, MD, 1994 - 1999

Ad Hoc Member, Chemoprevention Safety and Protocol Review Committee, National Cancer Institute, Bethesda, MD, 1994 - 2005

Member, Chemoprevention Agent Development Committee, National Cancer Institute, Bethesda, MD, 1994 - 2005

Institutional Committee Activities

Member, Selection Committee, German Prize for Cancer Prevention Research 2025, 2025 - Present

Member, AACR-Women in Cancer Research Charlotte Friend Lectureship Award, 2025 - 2026

Member, Executive Committee, iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium, 2024 - Present

Member, Texas Health Equity Alliance for Breast Cancer (THEAL) Internal Advisory Committee, 2023 - Present

Past Chair, Division Heads, 2023 - 2024

Member, Texas Business Women's Nominee Review Committee, 2022 - 2023

Observer/Advisor, Policy Management System Renovation Project Selection Committee, 2022 - Present

Chair, Division Heads, 2022 - 2023

Co-Chair, Rogers Award Selection Committee - Prevention, 2021

Member, Academic Policy Advisory Council, 2021 - Present

Member, Cancer Screening Task Force, 2021 - Present

Member, Global Oncology Strategy Workgroup, 2021 - Present

Team Lead - Clinical Prevention Services, Service Line Teams, 2021 - Present

Member, Research Enablement, Activities and Conduct Team (REACT), 2021 - Present

Member, Research Policy Advisory Council, 2021 - Present

Incoming Chair, Division Heads, 2021 - 2022

Member, Strategic Position Management Committee - Classified research and education positions, 2020 - 2023

Member, Promoting HPV Vaccination Among Texas Young Adults, 2020 - 2023

Faculty Co-Lead, Board of Visitors Cancer Prevention Committee, 2020 - 2024

Member, Strategic Position Management Committee, 2020 - 2022

Member, Sarcoma SPORE, 2019 - Present

Division Head for Cancer Prevention & Population Sciences, Division Heads, 2018 - Present

Member, Quasi-Endowment for the Underserved (COE Fund), 2018 - Present

Member, President's Advisory Committee, 2018 - Present

Member, Mexican-American Cohort Study, 2018 - Present

Member, Network Advisory Committee, 2018 - 2022

At-Large Member, Women's Leadership Network Steering Committee, 2018 - 2022

Member, Internal Advisory Board, 2018 - 2021

Member, Executive Committee, Komen Training Program to Reduce Breast Cancer Disparities in Black and Hispanic Women, 2018 - 2020

Member, Shared Resource Executive Committee, 2017 - 2019

Member, Institutional Biospecimen Utilization Committee (IBUC), 2017 - 2022

Co-Chair, Clinician Scientist Advisory Committee, 2017

Member, Women and Minority Faculty Inclusion, 2016 - 2023

Member, Head & Neck SPORE (P50), 2016 - Present

Chair, HPV SPORE (P50), 2016 - 2018

Chair, 2016 Rogers Award, 2016

Co-leader and Convener, CCSG Community Outreach & Engagement Leaders Team, 2016 - 2022

Member, International Cancer Control Partnership Steering Committee, 2015 - 2022

Member, MD Anderson Communications Advisory Committee, 2015 - 2017

Member, Executive Clinical Operations Team, 2015 - 2019

Member, Prostate Cancer SPORE (P50), 2014 - 2021

Team Member, Translational Research Strategic Planning Committee, 2014 - 2016

Member, Women Faculty Programs' Advisory Committee, 2014 - 2016

Member, GAP 2015 Conference, 2014 - 2015

Member, Cancer Medicine Division Head Search Committee, 2014 - 2015

Member, GAP International Advisory Board, 2014 - 2016

Member, Medical Quality Planning Committee, 2014 - 2019

Member, Clinical/Translational Awards Committee, 2013 - 2016

Member, Institutional Research Executive Committee (IREC), 2013 - 2015

Co-Chair, Internal Medicine Division Head Search Committee, 2013 - 2014

Member, Head and Neck Cancer SPORE (P50), 2013 - Present

Member, Institute for Cancer Care Excellence, 2012 - 2017

Member, Standing Committee on Faculty Awards, 2012 - Present

Member, Thoracic Head and Neck Medical Oncology Chair Search Committee, 2012 - 2013

Member, EVP and Provost Search Advisory Committee, 2012 - 2013

Member, David H. Koch Center for Prostate Cancer, 2012 - 2017

Member, Research Station, 2012 - 2014

Member, External Communications Advisory Committee, 2012 - 2017

Member, Institutional Clinical Executive Committee, 2011 - 2015

Member, Epidemiology Search Committee, 2011 - 2013

Session Co-Chair, Annual Symposia on Cancer Research, 2010

Co-Chair, Cancer Control Leadership Team, 2010 - 2024

Member, Molecular Testing Evaluation Committee, 2010 - Present

Co-Leader, GI Cancer Research Program, 2010 - 2022

Member, MD Anderson Survival Monograph Editorial Board, 2009

Member, Institutional Awards Committee, 2009 - Present

Chair, Comparative Effectiveness Research Grants Review Committee, 2009 - 2011

Chair, Duncan Institute Executive Committee, 2009 - Present

Member, Global Academic Programs Oversight Steering Committee, 2009 - 2014

Member, Margaret L. Kripke Legends Award, 2008 - Present

Member, Institute of Personalized Cancer Therapy (IPCT), 2008 - 2015

Member, Infrastructure/Animal Care Committee, 2008 - 2010

Member, 2008 Rogers Award, 2008

Member, Management Committee, 2008 - 2011

Member, Division Heads Committee, 2008 - 2012

Member, Cancer Prevention Research Training Program Advisory Committee, 2008 - Present

Member, Research Council, 2007 - 2013

Member, Research Strategies Advisory Committee, 2007 - 2012

Member, Executive Committee of the Medical Staff, 2007 - Present

Member, Translational Research Faculty Development Committee, 2007 - 2012

Member, CCSG Executive Committee, 2007 - Present

Member, Extramural Programs Oversight Steering Committee, 2007 - 2014

Member, PRS Executive Council, 2007 - Present

Member, Clinical Strategies Advisory Committee, 2007 - 2012

Member, President's Advisory Board, 2007 - 2015

Member, Clinical Research Council, 2007 - 2011

Honors & Awards

2015	2015 Provost's Distinguished Faculty Mentor Nominee, The University of Texas MD Anderson Cancer Center
2015	ASCO/American Cancer Society Award and Lecture, ASCO/American Cancer Society
2014	Cancer Prevention Fellowship Distinguished Alumni Award, National Cancer Institute, Department of Health & Human Services
2013	Eagle Award, Cancer Fighters of Houston, Inc
2011	Outstanding Leading Mentor in Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center
2007	On-the-Spot Award, National Cancer Institute
2007	The Nancy Terner Behrman Lecture in Honor of Betty Flehinger, PhD, Weill Cornell Medical School, NYC
2003	Service Award, National Cancer Institute
2002	On-the-Spot Award, National Cancer Institute
2002	Research Award, Distinguished Achievement in Cancer Prevention, National Cancer Institute
2002	Research Award, PLCO Ancillary Studies Project Team (Group Award), National Cancer Institute
1999	On-the-Spot Award, National Cancer Institute
1998 - 2000	Performance Awards, Department of Health and Human Services
1996	Scholarship, AACR/ASCO (First Joint) Workshop - Methods in Clinical Cancer Research, Park City, Utah
1994	Delta Omega Public Health Honor Society, Johns Hopkins Alpha Chapter
1986 - 1988	Outstanding, Emory University - Annual House Staff Evaluation Committee designations
1985	Outstanding, Emory University - Annual House Staff Evaluation Committee Designations
1981	Phi Beta Kappa, Wayne State University
1977 - 1981	Honors Program, Wayne State University, College of Liberal Arts
1977 - 1981	Scholarship (Full Tuition), Wayne State University
1977	Valedictorian, Madison High School

Professional Memberships

German Cancer Research Center

2021

American Public Health Association

2013 - Present

Cancer Prevention Research Institute of Texas

2011

International Society of Gastroenterological Carcinogenesis

2009 - 2012

Canadian Cancer Society/National Cancer Institute of Canada's Prevention Initiative

2006 - 2007

Rutgers Medical School University of Medicine and Dentistry of New Jersey

2004 - Present

National Eye Institute

2003 - Present

Cancer Research & Prevention Foundation

2002 - 2004

Lucie and Andre Chagnon Foundation - First International Symposium on Cancer Prevention

2002

Data and Safety Monitoring Board of HKU #7256/01M

2001 - 2005

Cancer Research Foundation of America

2000 - 2002

National Women's Health Resource Center

1999 - 2004

National Institute of Environmental Health Sciences

1998

Dutch Cancer Society

1998 - 2002

World Health Organization - International Agency for Research on Cancer

1997 - 1998

American Society of Clinical Oncology

1996 - Present

American Society of Preventive Oncology

1996 - Present

American Association for the Advancement of Science

1993 - 1999

American Association for Cancer Research

1993 - Present

American College of Physicians

1986 - Present

Selected Publications

Peer-Reviewed Articles

Hurst A, Karam-Hage M, Cofer J, Javaid M, Beneventi D, Hawk E, et al. A Tobacco Treatment Training Program Expands the Number of Healthcare Providers Trained to Use Evidence-Based Practices and Methods. ACEQI 1(1), 2025. e-Pub 2025.
Faupel-Badger, J, Kohaar, I, Bahl, M, Chan, AT, Campbell, JD, Hawk, E, et al. Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer 24(11):792-809, 2024. e-Pub 2024. PMID: 39354069.
Kwan S, Gonzales KA, Jamal MA, Stevenson HL, Tan L, Hawk ET, et al. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut microbes 16(1), 2024. e-Pub 2024. PMID: 39239875.
Love, B, Coffman, R, Ghosh, C, Cofer, J, Hurst, A, Hawk, E, et al. Implementation and Evaluation of a Multi-level, Place-Based Tobacco Prevention and Control Program at a Minority-Serving Institution in Texas. Prevention Science 25(6):898-909, 2024. e-Pub 2024. PMID: 39060839.
Schrank BR, Fuller JA, Gallagher CM, Morris VK, Holliday EB, Hawk E, et al. Institution-wide retreats foster organizational learning and action at a comprehensive cancer center. J Cancer Educ 39(4):368-373, 2024. e-Pub 2024. PMID: 38468110.
Hassan MM, Li D, Han Y, Byun J, Hatia RI, Hawk, E, et al. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
Torres HA, Mustafayev K, Juneau RP, Hwang JP, Wang LS, Hawk E, et al. Implementation of universal hepatitis c virus screening in a tertiary cancer center. J Natl Compr Canc Netw 22(2D):e237332, 2024. e-Pub 2024. PMID: 38729204.
Rechis R, Oestman KB, Walsh MT, Love B, Hawk E. Be Well™ Acres Homes: A community-driven, evidence-based approach to reduce health inequities through sustained cross-sector partnership. Cancer Causes Control 35(4):611-622, 2024. e-Pub 2024. PMID: 37979072.
Oestman, KB, Rechis, R, Williams, PA, Brown, JA, Treiman, K, Hawk, E, et al. Reducing risk for chronic disease: evaluation of a collective community approach to sustainable evidence-based health programming. BMC Public Health 24(1):240, 2024. e-Pub 2024. PMID: 38245669.
Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Hawk ET, et al. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in Lynch syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
Batman SH, Varon ML, Daheri M, Ogburn T, Rivas SD, Hawk E, et al. Addressing cervical cancer disparities in Texas: Expansion of a community-based prevention initiative for medically underserved populations. Prev Med Rep 36:102486, 2023. e-Pub 2023. PMID: 38021412.
Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, et al. Independent of primary sclerosing cholangitis and cirrhosis, early adulthood obesity is associated with cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 32(10):1338-1347, 2023. e-Pub 2023. PMID: 37540502.
Bello RS, Bello RS, Walsh MT, Walsh MT, Harper B, Harper B, Amos CE, Amos CE, Oestman K, Oestman K, Hawk E, Hawk E, et al, et al. Creating and activating an implementation community to drive HPV vaccine uptake in Texas: The role of an NCI-designated cancer center. Vaccines (Basel) 11(6), 2023. e-Pub 2023. PMID: 37376517.
Salcedo MP, Gowen R, Rodriguez AM, Fisher-Hoch S, Daheri M, Hawk E, et al. Addressing high cervical cancer rates in the Rio Grande Valley along the Texas-Mexico border: a community-based initiative focused on education, patient navigation, and medical provider training/telementoring. Perspect Public Health 143(1):22-28, 2023. e-Pub 2023. PMID: 34130548.
Torode JS, Tittenbrun Z, Romero Y, Johnson SE, Bourque JM, Hawk E, et al. Ten years of the international cancer control partnership: promoting national cancer control plans to shape the health system response for cancer control. JCO Glob Oncol 9, 2023. e-Pub 2023. PMID: 36630665.
Fokom Domgue J, Pande M, Yu R, Manjuh F, Welty E, Hawk E, et al. Development, implementation, and evaluation of a distance learning and telementoring program for cervical cancer prevention in Cameroon. JAMA Netw Open 5(11), 2022. e-Pub 2022. PMID: 36346631.
Berenson AB, Chang M, Hawk ET, Ramondetta LM, Hoang T. Vulvar cancer incidence in the US and its relationship to human papillomavirus vaccinations, 2001-2018. Cancer Prev Res (Phila) 15(11):777-784, 2022. e-Pub 2022. PMID: 35969832.
Kwan SY, Sabotta CM, Joon A, Wei P, Petty LE, Hawk ET, et al. Gut microbiome alterations associated with diabetes in Mexican Americans in South Texas. mSystems 7(3):e0003322, 2022. e-Pub 2022. PMID: 35477306.
Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Hawk ET, et al. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology 75(4):955-967, 2022. e-Pub 2022. PMID: 34633706.
Kisiel JB, Papadopoulos N, Liu MC, Crosby D, Srivastava S, Hawk ET. Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions. Cancer 128 Suppl 4(S4):861-874, 2022. e-Pub 2022. PMID: 35133659.
Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Hawk ET, et al. Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 30(9):1643-1651, 2021. e-Pub 2021. PMID: 34155064.
Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Hawk E, et al. Be Well Communities™: Mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control 32(8):859-870, 2021. e-Pub 2021. PMID: 34037915.
Hawk ET, Maresso KC. The ASPREE trial: An unanticipated stimulus for greater precision in prevention?. J Natl Cancer Inst 113(3):221-222, 2021. e-Pub 2021. PMID: 32778864.
Tami-Maury I, Suchil L, Reynales-Shigematsu LM, Garcia-Gomez L, Chen M, Hawk E, et al. Cross-sectional survey for assessing cancer care providers' characteristics and attitudes on smoking cessation in Colombia and Mexico. BMJ Open 11(2):e041447, 2021. e-Pub 2021. PMID: 33526497.
Guimarães DP, Mantuan LA, de Oliveira MA, Junior RLH, Mafra da Costa A, Hawk ET, et al. The performance of colorectal cancer screening in Brazil: the first two years of the implementation program in Barretos Cancer Hospital. Cancer Prev Res (Phila) 14(2):241-252, 2021. e-Pub 2021. PMID: 32998941.
Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Hawk ET, et al. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: A cross-sectional study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2021. PMID: 32314052.
Kripke M, Brody JG, Hawk E, Hernandez AB, Hoppin PJ, Rudel RA, et al. Rethinking environmental carcinogenesis. Cancer Epidemiol Biomarkers Prev 29(10):1870-1875, 2020. e-Pub 2020. PMID: 33004408.
Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Hawk E, et al. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020. e-Pub 2020. PMID: 32912193.
Liao Y, Basen-Engquist KM, Urbauer DL, Bevers TB, Hawk E, Schembre SM. Using continuous glucose monitoring to motivate physical activity in overweight and obese adults: A pilot study. Cancer Epidemiol Biomarkers Prev 29(4):761-768, 2020. e-Pub 2020. PMID: 32066620.
Abu-Sbeih H, Ali FS, Qiao W, Lum P, Shafi MA, Hawk E, et al. Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. J Cancer 11(11):3192-3198, 2020. e-Pub 2020. PMID: 32231724.
Chido-Amajuoyi OG, Mantey D, Cunningham S, Yu R, Kelder S, Hawk E, et al. Characteristics of US adults attempting tobacco use cessation using e-cigarettes. Addict Behav 100:106123, 2020. e-Pub 2020. PMID: 31605837.
Hawk ET, Colbert Maresso K. E-Cigarettes: Unstandardized, under-regulated, understudied - and unknown health and cancer risks. Cancer Res 79(24):6079-6083, 2019. e-Pub 2019. PMID: 31658978.
Fokom Domgue J, Baker E, Manjuh F, Lopez M, Welty T, Cameroon Cervical Cancer Prevention ECHO collaborative group, et al. Connecting frontline providers in Africa with distant experts to improve patients' outcomes through Project ECHO: a successful experience in Cameroon. Int J Gynecol Cancer 29(9):1446-1447, 2019. e-Pub 2019. PMID: 31118215.
Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Hawk E, et al. A pilot study evaluating organochlorine and organophosphate pesticide exposure in children and adolescents of Mexican descent residing in Hidalgo County, Texas. J Immigr Minor Health 21(4):751-760, 2019. e-Pub 2019. PMID: 30066057.
Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Hawk E, et al. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One 14(8):e0220814, 2019. e-Pub 2019. PMID: 31369653.
Huey RW, Hawk E, Offodile AC. Mind the gap: Precision oncology and its potential to widen disparities. J Oncol Pract 15(6):301-304, 2019. e-Pub 2019. PMID: 31112478.
Delacruz RGC, Sandoval IT, Chang K, Miller BN, Reyes-Uribe L, Hawk ET, et al. Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. Oncotarget 10(39):3939-3951, 2019. e-Pub 2019. PMID: 31231471.
Mackert M, Case K, Lazard A, Oh J, Wagner JH, Hawk E, et al. Building a health communication brand for University of Texas System tobacco control. J Am Coll Health 67(4):291-298, 2019. e-Pub 2019. PMID: 29952736.
Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Hawk ET, et al. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine 42:296-303, 2019. e-Pub 2019. PMID: 30905849.
Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Hawk E, et al. Real-time interrogation of aspirin reactivity, biochemistry, and biodistribution by hyperpolarized magnetic resonance spectroscopy. Angew Chem Int Ed Engl 58(13):4179-4183, 2019. e-Pub 2019. PMID: 30680862.
Cunningham SA, Yu R, Shih T, Giordano S, McNeill LH, Hawk E, et al. Cancer-related risk and beliefs in Texas: Findings from a 2018 population-level survey. Cancer Epidemiol Biomarkers Prev 28(3):486-494, 2019. e-Pub 2019. PMID: 30700446.
Dahlstrom KR, Sturgis EM, DePinho RA, Hawk E, Baum G. Knowledge about the human papillomavirus vaccine among employees at a tertiary cancer center: room for improvement. J Appl Res Child 10(2):Article 5, 2019. e-Pub 2019.
Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Hawk ET, et al. AACR white paper: Shaping the future of cancer prevention - a roadmap for advancing science and public health. Cancer Prev Res (Phila) 11(12):735-778, 2018. e-Pub 2018. PMID: 30530635.
Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Hawk ET, et al. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 2018. e-Pub 2018. PMID: 30412224.
Frech S, Muha CA, Stevens LM, Trimble EL, Brew R, Hawk ET, et al. Perspectives on strengthening cancer research and control in Latin America through partnerships and diplomacy: Experience of the National Cancer Institute's Center for Global Health. J Glob Oncol 2018(4):1-11, 2018. e-Pub 2018. PMID: 30241245.
Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, et al. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. e-Pub 2018. PMID: 30112590.
Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Hawk ET, et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
Lin SH, Raju GS, Huff C, Ye Y, Gu J, Hawk E, et al. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2018. PMID: 28607096.
Foxhall L, Moreno M, Hawk E. MD Anderson's population health approaches to cancer prevention. Tex Med 114(2):34-41, 2018. e-Pub 2018. PMID: 29393960.
Sivakumar S, San Lucas FA, McDowell TL, Lang W, Xu L, Hawk ET, et al. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res 77(22):6119-6130, 2017. e-Pub 2017. PMID: 28951454.
Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Hawk E, et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
Gausachs M, Borras E, Chang K, González S, Azuara D, Hawk E T, et al. Mutational heterogeneity in APC and KRAS arises at the crypt level and leads to polyclonality in early colorectal tumorigenesis. Clin Cancer Res 23(19):5936-5947, 2017. e-Pub 2017. PMID: 28645942.
Lopez MS, Baker ES, Milbourne AM, Gowen RM, Rodriguez AM, Hawk ET, et al. Project ECHO: A telementoring program for cervical cancer prevention and treatment in low-resource settings. J Glob Oncol 3(5):658-665, 2017. e-Pub 2017. PMID: 29094102.
Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawk E, et al. Beyond COX-1: The effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 36(2):289-303, 2017. e-Pub 2017. PMID: 28762014.
Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, et al. Building trust and diversity in patient-centered oncology clinical trials: An integrated model. Clin Trials 14(2):170-179, 2017. e-Pub 2017. PMID: 28166647.
Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Hawk ET, et al. Use of non-steroidal anti-inflammatory drugs in US adults: Changes over time and by demographic. Open Heart 4(1):e000550, 2017. e-Pub 2017. PMID: 28674622.
Hawk ET. Ernest Hawk discusses the NCI-designated cancer centers' joint statement on the HPV vaccine. Oncology (Williston Park) 30(7):599-600, 2016. e-Pub 2016. PMID: 27422108.
Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Hawk ET, et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res (Phila) 9(6):417-427, 2016. e-Pub 2016. PMID: 27221540.
Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Hawk ET, et al. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol 45(3):713-713F, 2016. e-Pub 2016. PMID: 26686840.
DePinho RA, Hawk E. Cancer prevention in developing countries: a vision for preserving health in Mexico. Salud Publica Mex 58(2):93-96, 2016. e-Pub 2016. PMID: 27557366.
Hildebrandt MA, Reyes ME, Lin M, He Y, Nguyen SV, Hawk ET, et al. Germline genetic variants in the Wnt/beta-catenin pathway as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 25(3):540-546, 2016. e-Pub 2016. PMID: 26809274.
Tsai KY, Hawk ET. When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila) 9(2):125-127, 2016. e-Pub 2016. PMID: 26714773.
Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Hawk E, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 65(2):286-295, 2016. e-Pub 2016. PMID: 25792707.
Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Hawk ET, et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 65(5):345-383, 2015. e-Pub 2015. PMID: 26284997.
Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, Hawk E, et al. Obesity early in adulthood increases risk but does not affect outcomes of Hepatocellular Carcinoma. Gastroenterology 149(1):119-129, 2015. e-Pub 2015. PMID: 25836985.
Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood A, Hawk ET. Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. Cancer Prev Res (Phila) 7(10):973-992, 2014. e-Pub 2014. PMID: 25060262.
Satcher RL, Bogler O, Hyle L, Lee A, Simmons A, Williams R, Hawk E, Matin S, Brewster AM. Telemedicine and telesurgery in cancer care: Inaugural conference at MD Anderson Cancer Center. J Surg Oncol 110(4):353-359, 2014. e-Pub 2014. PMID: 24889208.
Akiyama J, Akiyama J, Alexandre L, Alexandre L, Baruah A, Baruah A, Buttar N, Buttar N, Chandra R, Chandra R, Hawk E, Hawk E, et al, et al. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 1325(1):108-26, 2014. e-Pub 2014. PMID: 25266020.
Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient?. JAMA 312(12):1193-4, 2014. e-Pub 2014. PMID: 25247511.
Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS, et al. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: A current view and opportunities for improvement. Cancer 120 Suppl S7:1113-1121, 2014. e-Pub 2014. PMID: 24643649.
Herbst RS, Hobin JA, Gritz ER, on Tobacco WCFTAS, Cancer [Hawk E, WK] H. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res 20(7):1709-18, 2014. e-Pub 2014. PMID: 24691637.
Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, APC Trial Collaborators APC, Kubo M, et al.. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 19(23):6430-7, 2013. e-Pub 2013. PMID: 24084763.
Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 34(12):2750-6, 2013. e-Pub 2013. PMID: 23996928.
Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog 52 Suppl 1(SUPPL1):139-47, 2013. e-Pub 2013. PMID: 23776098.
Coxib, (CNT) Collaboration TNT, Bhala N, Emberson J, Merhi A, Hawk E, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769-79, 2013. e-Pub 2013. PMID: 23726390.
Raju GS, Vadyala V, Slack R, Krishna SG, Ross WA, Hawk E, et al. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med 2(3):391-402, 2013. e-Pub 2013. PMID: 23930215.
Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hawk E, et al. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 2013. e-Pub 2013. PMID: 23466817.
Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Hawk E, et al. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med 2(1):108-15, 2013. e-Pub 2013. PMID: 24279005.
Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, et al. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer 118(24):6188-6198, 2012. e-Pub 2012. PMID: 22673945.
Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Hawk E, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 104(20):1599-611, 2012. e-Pub 2012. PMID: 23073549.
Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Hawk ET, et al. Genetic polymorphisms in MicroRNA-Related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 18(14):3982-91, 2012. e-Pub 2012. PMID: 22661538.
Dai J, Gu J, Huang M, Eng C, Kopetz ES, Hawk E, et al. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
Cialdella-Kam L, Sabado P, Bispeck MK, Silverman S, Bernstein L, Hawk E, et al. Implementing Cancer Prevention into Clinical Practice. J Cancer Educ 27(Suppl 2):S136-43, 2012. e-Pub 2012. PMID: 22367592.
Lin M, Eng C, Hawk E, Huang M, Greisinger AJ, Gu J, et al. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis 33(4):841-7, 2012. e-Pub 2012. PMID: 22318908.
Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Hawk ET, et al. The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. Clin Ther 34(3):569-79, 2012. e-Pub 2012. PMID: 22386831.
Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hawk E, et al. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer 3(1):16-22, 2012. e-Pub 2012. PMID: 22893787.
Lin J, Forman MR, Wang J, Grossman HB, Chen M, Hawk ET, et al. Intake of red meat and heterocyclic amines, metabolic pathway genes, and bladder cancer risk. Int J Cancer 131(8):1892-1903, 2012. e-Pub 2012. PMID: 22261697.
Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma. Cancer Prev Res (Phila) 5(1):61-72, 2012. e-Pub 2012. PMID: 22030088.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, PLCO Project Team, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125-32, 2012. e-Pub 2012. PMID: 22228146.
Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 4(11):1728-35, 2011. e-Pub 2011. PMID: 21778329.
Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment. Cancer Prev Res (Phila) 4(8):1172-80, 2011. e-Pub 2011. PMID: 21816845.
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, PLCO Project Team, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22):2295-303, 2011. e-Pub 2011. PMID: 21642681.
Lin M, Hawk E, Huang M, Lin J, Gu J, Ellis LM, et al. Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). J Clin Oncol 29(15_suppl):3529, 2011. e-Pub 2011. PMID: 22673945.
Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Chromosomal Aberrations Predict Malignant Progression of Esophageal Adenocarcinoma: a Genome-wide High-Density SNP Array Analysis. Cancer Prev Res (Phila) 3(9):1176-86, 2010. e-Pub 2010. PMID: 20651033.
Brewster AM, Patterson SL, Forman MR, Hughes-Halbert C, Limburg PJ, Hawk ET, et al. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila Pa) 3(8):1044-8, 2010. e-Pub 2010. PMID: 20663980.
Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105(6):1437-43, 2010. e-Pub 2010. PMID: 20234350.
Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 3(5):588-96, 2010. e-Pub 2010. PMID: 20403998.
Hawk E, Patterson S. Modelling a dream: the molecular prevention of pancreatic cancer. Gut 59(5):566-8, 2010. e-Pub 2010. PMID: 20427387.
Chan AT, Zauber AG, Meier H, Breazna A, Hunter DJ, Hawk ET, et al. Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 136(7):2127-2136.e1, 2009. e-Pub 2009. PMID: 19233181.
Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Hawk E, et al. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 7(5):568-74, 2009. e-Pub 2009. PMID: 19418605.
Bertagnolli MM, Bertagnolli MM, Eagle CJ, Eagle CJ, Zauber AG, Zauber AG, Redston M, Redston M, Breazna A, Breazna A, Hawk ET, Hawk ET, et al, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2(4):310-21, 2009. e-Pub 2009. PMID: 19336730.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, PLCO Project Team, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-9, 2009. e-Pub 2009. PMID: 19297565.
Hawk E, Guillem JG. Improving the Vision of Colonoscopy: Does the Fine Print Really Matter?. Cancer Prev Res (Phila) 1(7):495-498, 2008. e-Pub 2008. PMID: 19138997.
Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET, et al. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res 14(18):5672-7, 2008. e-Pub 2008. PMID: 18794074.
Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, et al. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res 14(18):5707-13, 2008. e-Pub 2008. PMID: 18794079.
Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, et al. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res 14(18):5664-71, 2008. e-Pub 2008. PMID: 18612047.
Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. Cancer Prev Res (Phila Pa) 1(1):32-38, 2008. e-Pub 2008. PMID: 18841250.
Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Hawk ET, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 1(1):21-31, 2008. e-Pub 2008. PMID: 19138933.
Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead?. Am J Gastroenterol 103(4):838-41, 2008. e-Pub 2008. PMID: 18371147.
Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Hawk E, et al. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials The Cross Trial Safety Analysis. Circulation 117(16):2104-13, 2008. e-Pub 2008. PMID: 18378608.
Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Hawk E, et al. Secondary chemoprevention of Barrett's Esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99(7):545-557, 2007. e-Pub 2007. PMID: 17405999.
Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Hawk ET, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007. e-Pub 2007. PMID: 17655039.
Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Hawk E, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114(10):1028-1035, 2006. e-Pub 2006. PMID: 16943394.
Hawk ET, Viner JL. Do statins prevent cancer?. Nat Clin Pract Oncol 3(9):478-9, 2006. e-Pub 2006. PMID: 16955084.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Hawk ET, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-84, 2006. e-Pub 2006. PMID: 16943400.
Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Hawk ET, et al. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res 66(13):6851-60, 2006. e-Pub 2006. PMID: 16818663.
Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Hawk E, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15(7):1382-1391, 2006. e-Pub 2006. PMID: 16835340.
Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Hawk ET, et al. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 15(5):1046-7, 2006. e-Pub 2006. PMID: 16702392.
Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129(3):863-73, 2005. e-Pub 2005. PMID: 16143126.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Hawk E, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-80, 2005. e-Pub 2005. PMID: 15713944.
Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Hawk E, et al. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol 22(19):3848-51, 2004. e-Pub 2004. PMID: 15353541.
Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Hawk E, et al. A randomized phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10(19):6502-11, 2004. e-Pub 2004. PMID: 15475437.
Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 127(3):838-44, 2004. e-Pub 2004. PMID: 15362039.
Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5B):3177-84, 2004. e-Pub 2004. PMID: 15510608.
Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Hawk ET, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6):920-7, 2004. e-Pub 2004. PMID: 15184247.
Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Hawk ET, et al. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64(8):2904-9, 2004. e-Pub 2004. PMID: 15087410.
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Hawk ET, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261-8, 2004. e-Pub 2004. PMID: 14970275.
Viner JL, Hawk E. Commentary on Chan, et al. N Am Menopause Soc J 11(3), 2004. e-Pub 2004.
Hawk ET, Viner JL. Aspirin: still learning about the wonder drug. Gut 52(11):1535-6, 2003. e-Pub 2003. PMID: 14570718.
Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res 63(18):5649-55, 2003. e-Pub 2003. PMID: 14522879.
Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Hawk E, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755-62, 2003. e-Pub 2003. PMID: 12917207.
Hawk E, Viner JL, Umar A, Anderson WF, Sigman C, Guyton KZ. Cancer and the cyclo-oxygenase enzyme: implications for treatment and prevention. Amer J Cancer 2:27-55, 2003. e-Pub 2003.
Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst 94(15):1126-1133, 2002. e-Pub 2002. PMID: 12165637.
Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Hawk E, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94(13):1001-9, 2002. e-Pub 2002. PMID: 12096085.
Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857-60, 2002. e-Pub 2002. PMID: 12010890.
Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Hawk E, et al. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev 10(3):201-8, 2001. e-Pub 2001. PMID: 11303588.
Hawk ET, Hawk ET, Viner JL, Viner JL, Anderson BF, Anderson BF. Development of COX inhibitors as cancer chemopreventives. ASCO Educational Book:28-37, 2001. e-Pub 2001.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-52, 2000. e-Pub 2000. PMID: 10874062.
Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60(7):1864-70, 2000. e-Pub 2000. PMID: 10766173.
Hawk E, Limburg P, Lubet R. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63, 1999. e-Pub 1999. PMID: 10630181.
Lam S, leRiche JC, Zheng Y, Coldman A, MacAulay C, Hawk E, et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 91(8):691-6, 1999. e-Pub 1999. PMID: 10218506.
Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Hawk E, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20(3):425-30, 1999. e-Pub 1999. PMID: 10190557.
Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20(2):185-91, 1999. e-Pub 1999. PMID: 10069452.
Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Hawk E, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 470:45-53, 1999. e-Pub 1999. PMID: 10709673.
Hawk ET, Limburg PJ. Agent development in colorectal cancer chemoprevention: current status and future trends. ASCO Educational Book:193-9, 1999. e-Pub 1999.
Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 44(2):420-7, 1998. e-Pub 1998. PMID: 9474054.
Hawk E, Doeltz MK, Kelloff GK. Indomethacin - toxicology and safety. Contribution to IARC Handbooks of Cancer Prevention - Non-steroidal Anti-inflammatory Drugs (International Agency for Research on Cancer, Lyon) 1:151-197, 1997. e-Pub 1997.
Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Steele VE, Lubet RA, et al. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev 5(2 Suppl):79-85, 1996. e-Pub 1996. PMID: 9061299.
Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17(7):1435-8, 1996. e-Pub 1996. PMID: 8706245.
Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 25:1-14, 1996. e-Pub 1996. PMID: 9027592.
Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Hawk ET, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 26(SUPPL. 26):1-28, 1996. e-Pub 1996. PMID: 9154166.
Kelloff G, Kelloff G, Boone C, Boone C, Steele V, Steele V, Crowell J, Crowell J, Lubet R, Lubet R, Hawk E, Hawk E, et al, et al. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ(139):203-19, 1996. e-Pub 1996. PMID: 8923032.
Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, et al. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 63(26 Suppl):54-71, 1996. e-Pub 1996. PMID: 9154168.
Kelloff G, Boone C, Crowell J, Nayfield S, Hawk E, Steele VE, et al. Development of breast cancer chemopreventive drugs. Breast J 1:271-83, 1995. e-Pub 1995.

Invited Articles

Cofer J, Hurst AN, Winter T, Moreno M, Cinciripini PM, Hawk E, et al. A comprehensive program to reduce tobacco-related cancers through actions by a national cancer institute-designated cancer center. Cancer Control 29, 2022. e-Pub 2022. PMID: 36373741.
Maresso KC, Hawk ET. A new year, a healthier you: 5 actions to reduce your cancer risk. Magazine of the National Association of Petroleum Engineers (NAPE)(January 2020):42-44, 2020. e-Pub 2020.
Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in colorectal cancer: predicting more than risk?. Cancer Prev Res (Phila) 7(10):969-972, 2014. e-Pub 2014. PMID: 25070664.
Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Hawk ET, et al. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res 3(4):505-17, 2010. e-Pub 2010. PMID: 20354165.
Hawk E, Patterson S. Aspirin: anti-colorectal adenocarcinoma activity in the adjuvant arena?. Future Oncol 6(2):197-200, 2010. e-Pub 2010. PMID: 20146578.
Hawk E, Patterson S. Statins: assessing their effects on cancer risk. NYP Cancer Prevention Newsletter(14), 2010. e-Pub 2010.

Editorials

Hill, DG, Hawk, E. Decision in Braidwood v. Becerra increases uncertainty in coverage for cancer screenings. Cancer 131(2):e35689, 2025. PMID: 39668522.
Hawk E, Martch SL. Recent American college of physicians guidance statement for screening average-risk, asymptomatic adults for colorectal cancer. Cancer Prev Res (Phila) 17(1):1-6, 2024. PMID: 38173395.
Cohen L, Hawk E. It doesn't need to take 25 years: emphasizing cancer prevention and control in President Biden's Cancer Moonshot. JCO Oncol Pract 19(10):831-34, 2023. PMID: 37672725.
Agbafe V, Berlin NL, Butler CE, Hawk E, Offodile Ii AC. Prescriptions for mitigating climate change-related externalities in cancer care: A surgeon's perspective. J. Clin. Oncol 40(18):1976-1979, 2022. PMID: 35333584.
Hawk E, Maresso KC. Aspirin use and cancer prevention: long-term data needed on benefits and risks. The ASCO Post, 2019.
Hawk E, Maresso KC, Brown P. NSAIDs to prevent breast cancer recurrence? An unanswered question. J Natl Cancer Inst 110(9):927-28, 2018. PMID: 29554350.
Mahon SM, Hawk E. Introduction. Semin Oncol Nurs 32(3):185-6, 2016. PMID: 27539274.
Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol 2(6):770-771, 2016. PMID: 26939883.
Brenner DE, Hawk E. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila) 6(2):71-3, 2013. PMID: 23333813.
Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, et al. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila) 1(6):393-5, 2008. PMID: 19138984.
Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, et al. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev 17(11):2903-5, 2008. PMID: 18990728.
Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev 16(2):185-7, 2007. PMID: 17301246.
Hawk E, Viner JL. Statins and cancer-beyond the "one drug-one disease" model. N Engl J Med 352(21):2238-9, 2005. PMID: 15917390.
Hawk E, Viner JL. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev 14(2):297-8, 2005. PMID: 15734949.
Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Counterpoint: because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12(7):593-6, 2003. PMID: 12869396.
Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst 94(8):545-6, 2002. PMID: 11959883.
Hawk ET, Viner JL. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med 134(2):158-60, 2001. PMID: 11177320.
Hawk E. Patient needs, physician opportunities, and reimbursement align...Can our clinical practices do similarly?. ASCO Daily News.

Abstracts

Si M, Martch S, Shete S, Hawk E. Abstract LB143: Environmental assessment of alcohol-related policies and practices at US cancer organizations. AACR Annual Meeting 2024 84(7 Suppl):LB143, 2024. e-Pub 2024.
Salcedo MP, Gowen R, Lopez M, Baker E, Rodriguez AM, Hawk E, et al.. Addressing the high cervical cancer rates along the Texas-Mexico border through community outreach, patient navigation, and provider training/telementoring. 50th Annual Meeting of the Society of Gynecologic Oncology 154(S1):115, 2019. e-Pub 2019.
Abu-Sbeih H, Ali F, Qiao W, Lum P, Shafi M, Hawk E, et al. Risk of colonic adenoma in patients with non–colorectal cancers. J Clin Oncol 37(15 suppl):e13070, 2019. e-Pub 2019.
Shalaby AS, Botrus G, Kaseb AO, Li D, Abdel-Wahab R, Hawk E, et al. The Protective Effect of physical activity on Risk of Hepatocellular Carcinoma in USA. J Clin Oncol 34(15 Suppl):e15642, 2016. e-Pub 2016.
Hassan M, Li D, Kaseb A, Abbruzzese JL, Hassabo H, Hawk E, et al. Early obesity and risk of hepatocellular carcinoma in USA. 52nd Annual Meeting of the Society of Toxicology 132:519, 2013. e-Pub 2013.
Hawk E. Clinical agent development for colorectal cancer prevention. 3rd International Cancer Research Symposium 2012: Defining & Translating Science for Disease Prevention and Therapy 7:63, 2013. e-Pub 2013.
Lynch P, Rodriguez-Bigas M, Burke C, Phillips R, Wang X, Hawk E, et al. An international, randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Digestive Disease Week 2012 75(4 Suppl):AB285, 2012. e-Pub 2012.
Foxhall L, Patterson S, Silvas E, Galendez M, Furlan E, Hawk E. Comprehensive cancer control plan implementation at an NCI comprehensive cancer center. Innovations in Cancer Prevention and Research Conference, Cancer Prevention and Research Institute of Texas (CPRIT), 2011.
Peleg S, Shukla V, Mazumdar A, Curley SA, Hawk E, Brown PH, et al. High Dose Vitamin D Suppresses Growth of HCC Cell Lines and Reduces Hepatocyte Proliferation in β2–spectrin+/- Mice. Hepatology 54(4 Suppl):1304A, 2011. e-Pub 2011.
Lutz TA, Lopez R, Burke CA, Lynch P, Hawk E, Griebel D, et al. Is hearing loss an extracolonic manifestation of FAP?. Am J Gastroenterol 101(Suppl 554):1456, 2006. e-Pub 2006.
Burke CA, Lynch PM, Phillips R, Hawk E, Church J, Hasson H, et al. Considerations for maximizing randomization in chemoprevention trials in FAP. Familial Cancer 4:76-77, 2005. e-Pub 2005.
Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayes GD. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. Familial Cancer 4:57, 2005. e-Pub 2005.
Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, et al. Efficacy and safety in a phase I safety trial of celecoxib in children with FAP. AGA, 2005.
Peterson SK, Askins MA, Watts BG, Burke CA, Hasson H, Hawk E, et al. Family resiliency and functioning among families with APC-positive children. Familial Cancer 4(1 Suppl):49-50, 2005. e-Pub 2005.
Burke C, Hawk E, Eagle C, Wolog M, Church J, Hasson H, et al. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Familial Cancer 4:77-8 (A P29), 2005. e-Pub 2005.
Peterson SK, Lynch PM, Burke C, Church J, Hasson H, Hawk E. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. CGA, 2004. e-Pub 2004.
Half E, Su LK, Lunagomez S, Steinbach G, Patterson S, Hawk E, et al. Response to celecoxib in familial adenomatous polyposis (FAP) does not depend on genotype or adenoma burden. Digestive Disease Week 2004, 2004.
Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). Am J Gastroenterol 94(9):440, 1999. e-Pub 1999.
Lynch PM, Steinbach G, Hittelman W, Terry N, Frazier M, Hawk E, et al. A phase II chemoprevention trial in HNPCC utilizing a selective cyclooxygenase 2 inhibitor: protocol description and progress to date. J Gastroenterol Hepatol 14(8):A59, 1999. e-Pub 1999.
Yao Z, Jogunoori W, Peleg S, Amdur R, Patel K, Hawk E, et al. Restoration of Key TGF-β signaling Proteins by Vitamin D in Cirrhotic Human Livers with and without Hepatocellular Carcinoma (HCC). AASLD.
Peleg S, Shetty K, Shukla V, Amdur R, Patel K, Hawk E, et al. Vitamin D as a Chemopreventive Agent for Hepatocellular Carcinoma (HCC). AASLD.
Hassan M, Abdel-Wahab R, Wolff RA, Botrus G, Shalaby A, Hawk E, et al. Growth Hormone and Hepatocellular Carcinoma. The Liver Meeting 2016 – The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Hassan M, Abdel-Wahab R, Kaseb AO, Shalaby A, Botrus G, Hawk E, et al. Hepatocellular carcinoma screening in high-risk populations in the united states. The Liver Meeting 2016 – The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

Book Chapters

Maresso, KC, Basen-Engquist, KM, Hawk, E. Cancer epidemiology, prevention, and survivorship. In: Perioperative Care of the Cancer Patient, 3-14, 2023.
Bevers T, El-Serag H, Hanash S, Thrift AP, Tsai K, Hawk E, et al. Screening and early detection. In: Abeloff's Clinical Oncology. 6th. Elsevier, 375-98.e7, 2019.
Basen-Engquist K, Brown P, Coletta AM, Savage M, Maresso KC, Hawk E. Lifestyle and cancer prevention. In: Abeloff's Clinical Oncology. 6th. Elsevier, 337-74, 2019.
Menter, DG, Davis, JS, Tucker, SC, Hawk, E, Crissman, JD, Sood, AK, et al. Platelets: "First responders" in cancer progression and metastasis. In: Platelets in Thromb. and Non-Thromb. Disord.: Pathophysiol., Pharmacol. and Ther.: an Update. Springer, 1111-32, 2017.
Colbert Maresso K, Hawk E. Designing the chemoprevention trials of tomorrow: applying lessons learned from past definitive trials. In: Cancer prevention: dietary factors and pharmacology. Humana Press, 265-84, 2013.
Bevers TB, Brown PH, Maresso KC, Hawk ET. Cancer prevention, screening, and early detection. In: Abeloff's Clinical Oncology. 5th. Elsevier, 322-59, 2013.
Hawk ET, Patterson SL, Mishra L, Patel KK. Colorectal cancer prevention and aging. In: Cancer and Aging Handbook: Research and Practice. John Wiley & Sons, 85-96, 2012.
Viner JL, Hawk E, Lippman S. Cancer chemoprevention. In: Cancer epidemiology and prevention. 3rd. Oxford Univ. Press, 1318-40, 2006.
Hawk E. COX-2 in cancer. In: Targeted cancer therapies, an odyssey: tromsø symposium 2003. Tromso Univ. Press, 92-5, 2003.
Hawk E, Sigman CC, Kelloff G. Prevention of gastrointestinal cancers. In: Gastrointestinal oncology. Saunders, 205-14, 2003.
Anderson WF, Umar A, Viner JL, Hawk ET. Potential role of NSAIDs and COX-2 blockade in cancer therapy. In: COX-2 blockade in cancer prevention and therapy. Humana, 313-40, 2003.
Hawk ET, Viner JL, Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2 selective inhibitors in clinical cancer prevention trials. In: COX-2: a new target for cancer prevention and treatment. Karger, 210-42, 2003.
Hawk ET, Viner JL, Limburg PJ. Epidemiology and prevention of colorectal cancer. In: Gastrointestinal oncology. Oxford Univ. Press, 593-634, 2003.
Viner J, Richmond E, Hawk E, Lawrence J. Chemoprevention. In: The cancer handbook. Nature, 1417-38, 2002.
Watson AJM, Hawk E, DuBois RN. Chemoprevention of colorectal cancer. In: Gastrointestinal oncology. 1. Saunders, 421-428, 2002.
Schatzkin A, Goldstein A, Hawk E. Chemo-and dietary prevention of familial cancer: from theory to practice. In: Familial cancer and prevention: molecular epidemiology: a new strategy. Wiley & Sons, 295-301, 1999.

Books (edited and written)

Hawk E. Holland-Frei Cancer Medicine, 10th edition. Ed(s) 10th. Wiley-Blackwell, 2023.
Jankowski J, Hawk E. Handbook of gastrointestinal cancer. John Wiley & Sons, 2012.
Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention. Humana Press, 2005.
Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention. Humana Press, 2004.

Letters to the Editor

Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, et al. Assessment of compliance with Texas legislation banning indoor UV tanning by minors. JAMA Dermatol 153: 228-229, 2017.
Hawk E, Prindiville S, Kelloff G. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology 110: 654-5, 1996.

Less

Selected Presentations & Talks

Local Presentations

2019. Houston Business Coalition on Health. Houston, TX, US.
2019. Building a Cancer Prevention Program. Houston, TX, US.
2018. Aspirin as a Cancer Preventive Agent Existing Evidence & Remaining Questions. Houston, TX, US.
2014. EndTobacco Initiative/Institutional Advancement Grand Rounds. Houston, TX, US.
2013. Chemoprevention of Colorectal Cancer/Institutional Grand Rounds. Houston, TX, US.
2012. Retooling for a Healthier Community with the Affordable Care Act. 9th Annual Symposium. Houston, TX, US.
2011. 2011 Cancer Survivorship Research Symposium. Panelist. Houston, Texas, US.
2011. Advancing GI Cancer Prevention/Grand Rounds. Houston, TX, US.
2009. Tobacco Dependence: Risk, Treatment Strategies and Community Applications/Institutional Grand Rounds. Houston, TX, US.
2008. The Development of Anti-inflammatories for Cancer Prevention: From Fame to Flames ... to Phoenix?/Grand Rounds. Houston, TX, US.
2006. NCI's Current & Future Commitment to Translational Cancer Research. Translational Science Research Symposium. Baltimore, MD, US.
2005. Cancer Chemoprevention. Fundamentals of Clinical Oncology for Public Health Practitioners. Baltimore, MD, US.
2004. Clinical Prevention Trial Design - New and Emerging Concepts. Rockville, MD, US.
2004. Cancer Chemoprevention with Aspirin - Where We Are, Where We're Going. Third Annual SCORE Symposium. Bethesda, MD, US.
2002. Colon Cancer Prevention - What Internists Need to Know/ Medical Grand Rounds. Bethesda, MD, US.
2001. Current Standards for Colorectal Cancer Screening - Realizing Prevention's Promise. Tomorrow's Cancer Medicine Today: Latest Developments in Treatment and Prevention of Colorectal Cancer. Bethesda, MD, US.
2001. Colorectal Cancer Epidemiology and Prevention. Montgomery County Cancer Crusade Forum. Rockville, MD, US.
2000. Colon Cancer Prevention: Turning Current and Future Opportunities into Practice. First Membership Meeting of the Colon Cancer Alliance. Washington, DC, US.
2000. Colorectal Cancer Prevention - Current and Future Options. Invited. Baltimore, MD, US.
1996. The Agents, Biomarkers, and Cohorts of Cancer Chemoprevention Trials. NCI/USUHS Seminar. Bethesda, MD, US.

Regional Presentations

2022. Preneoplastic Conditions as a Model for Early Detection/ Plenary Session. AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer. Austin, TX, US.
2019. Healthier Texas Summit. Austin, TX, US.
2018. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. Preventive Medicine and Community Health Departmental Seminar Series. Galveston, TX, US.
2009. CPRIT Foundation's Policy Roundtable Meeting. Panelist. Austin, Texas, US.
2009. Progress in Translational Cancer Prevention. Austin, TX, US.
2004. Cancer Chemoprevention - From Emerging to Emerged. Cancer Education Consortium - Fellows Symposium in Cancer Pharmacology. Leesburg, VA, US.
2003. Colorectal Cancer Screening & Prevention - Putting Theory into Practice. Arlington, VA, US.
2003. Cancer Chemoprevention. Cancer Education Consortium on Pharmacology. Reston, VA, US.
2002. Colorectal Cancer: Current and Future Opportunities in Prevention and Treatment. Brown Bag Lunch Seminar. Washington, DC, US.
2001. COX-2 Inhibition in Cancer Prevention and Treatment. Invited. 2001 Winter Meeting. Washington, DC, US.
2001. COX-2 Inhibitors in Cancer Chemoprevention. Basic Science Conference. Washington, DC, US.

National Presentations

2025. Current State of Chemoprevention, from Biology to the Community. Invited. ASPO 49TH Annual Meeting. Philadelphia, Pennsylvania, US.
2022. Panelist, Preneoplasia: Definitions, Precancer Atlas and Resources. AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer. Austin, TX, US.
2022. Cancer Prevention and Interception. AACR Annual Meeting 2022. New Orleans, LA, US.
2022. Detecting Precancerous Lesions via MCED Testing. AACR Annual Meeting 2022. New Orleans, LA, US.
2022. Innovative Approaches for Implementation – Community, Regulatory, and Operational/ Plenary Session. AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer. Austin, TX, US.
2022. Panelist, What can we learn from trials that return unexpected results on mortality benefit from early detection biomarkers/tests?. Early Detection of Cancer Conference. Portland, OR, US.
2021. Surrogate Endpoints Issues and Opportunities/ Panel. Invited. Virtual, US.
2021. Cancer Prevention for the Practicing Clinician: Recommendations for Patients and Families. Invited. 2021 Cancer Care Symposium. Virtual, TX, US.
2021. The Possible Future of Liquid Biopsy in Cancer Prevention. Invited. NCI Symposium on Charting the Course of Liquid Biopsy in Precision Prevention and Treatment. Virtual, US.
2021. Moderator, Academic-Industry Partnership Forum. Invited. 12th Early Detection Research Network (EDRN) Scientific Workshop. Virtual, US.
2021. Overview of NSAIDs with Focus on Coxib in Cancer Prevention. Invited. Think Tank on Aspirin and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in Cancer Prevention. Virtual, US.
2021. Choosing the Population and Endpoints for a Trial. Invited. Cancer Screening Trial Network Workshop. Virtual, US.
2020. Universal Cancer Screening Summit. Rochester, MD, US.
2019. Addressing the high cervical cancer rates along the Texas-Mexico border through community outreach, patient navigation, and provider training/telementoring. Poster. 50th Annual Meeting of the Society of Gynecologic Oncology. Honolulu, Hawaii, US.
2019. Models for Population Health Improvement by Health Care Systems and Partners: Tensions and Promise on the Path Upstream Workshop. Washington, DC, US.
2019. Evidence-Based Examples of Effective Cancer Prevention and Control. The Coalition for Better Health at Lower Cost. New York, NY, US.
2019. Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families. Invited. Banner Health Regional Cancer Conference. Loveland, CO, US.
2019. Panelist, Key Challenges in Clinical Trial Data Sharing and Reuse. Invited. Sharing Clinical Trial Data: Challenges and a Way Forward: A Workshop. Washington, D.C, US.
2018. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. Fox Chase Cancer Prevention Symposium. Philadelphia, PA, US.
2017. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. New Orleans, LA, US.
2017. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach/Grand Rounds. Omaha, NE, US.
2016. Integrating Cancer Prevention Through Personal & Public Actions/Grand Rounds. Invited. Iowa City, IA, US.
2016. Cancer Prevention as an Urgent Priority: Driving Progress Through Molecular & Translational Research, as well as Population-Based Actions. Distinguished Scientist Seminar. Mobile, AL, US.
2015. Advancing Cancer Prevention & Control as "Plan A". The Sidney Kimmel Comprehensive Cancer Center Visiting Professor Lecture Series. Baltimore, MD, US.
2015. Advancing Cancer Prevention & Control as "Plan A". Visiting. Daniel G. Miller Lectureship. New York, NY, US.
2014. Advancing Cancer Prevention & Control as Plan A: Perspectives from a Former Cancer Prevention Fellow. Cancer Prevention and Control Colloquia Series. Bethesda, MD, US.
2013. The Gold Standard's Impact on Communities. Panelist. CEO Roundtable XII. Cary, North Carolina, US.
2013. Prevention in a NCI-designated Cancer Center- Distraction or Distinction?. Omaha, NE, US.
2013. Colorectal Cancer Prevention: What We've Learned, Where We're Going, How We'll Get There. Omaha, NE, US.
2011. Advancing Population Science Research in Cancer. Rochester, MN, US.
2009. The Development of Anti-Inflammatories for Cancer Prevention - From Fame, to Flames, to Phoenix? / Grand Rounds. Madison, WI, US.
2009. Development of Anti-inflammatories for Cancer Prevention - From Fame to Flames…to Phoenix?. Chemoprevention Lecture Series. Chicago, IL, US.
2009. NSAIDs in Cancer Chemoprevention - From Fame to Flames...to Phoenix?. Tucson, AZ, US.
2009. Principles of Cancer Prevention: Interventions that Reduce Cancer Risk and Progression. Johnson City, TN, US.
2008. Chemoprevention in the Era of Personalized Medicine: Recent Advances. Panelist. AACR Annual Meeting 2008. San Diego, California, US.

International Presentations

2018. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. DKFZ Conference on Preventive Oncology: Facing the Challenges of Cancer Prevention and Early Detection, DE.
2012. Molecular Basis of Chemoprevention. 305th Dr. Luis Guerrero Memorial Lecture. Manila, PH.
2012. Prevention in a Cancer Center: Revolution or Evolution?. The Gina V. Panuncialman Memorial Lecture. Manila, PH.

Formal Peers

2022. Evidence-Based Innovative Cancer Control Programs Accelerating Implementation of Cancer Control Programs in APEC Economies through Innovation and Partnership. Invited. Virtual, US.
2019. Strategic Planning Working Group. Invited. Bethesda, MD, US.
2019. Cancer Prevention Steering Committee Annual Meeting. Invited. Washington, DC, US.
2009. Integrated, Multi-disciplinary Translational Research Across a Disease Spectrum Using the NCI Translational Research Working Group (TRWG) Pathways Model. Invited. Philadelphia, PA, US.
2007. Cancer Chemoprevention. Invited. Baltimore, MD, US.
2007. The Future of Translational Science in Cancer. Invited. Bethesda, MD, US.
2007. Colorectal Cancer Prevention. Invited. Bethesda, MD, US.
2006. The Future of Translational Science in Cancer. Invited. Bethesda, MD, US.
2006. Cancer Chemoprevention. Invited. Baltimore, MD, US.
2006. Translational Research Working Group - Interim Report. Invited. Bethesda, MD, US.
2006. The NCI's Translational Research Working Group - Envisioning the Future of Translational Cancer Research. Invited. Washington, DC, US.
2006. Translational Research Working Group - Interim Report. Invited. Bethesda, MD, US.
2006. The NCI's Translational Research Working Group - Envisioning the Future of Translational Cancer Research. Invited. Washington, DC, US.
2006. Translational Research Working Group. Invited. Gaithersburg, MD, US.
2006. The Future of Cancer Prevention Research & How to Find Your Place in It. Invited. Bethesda, MD, US.
2006. The NCI's Translational Research Working Group - Envisioning the Future of Translational Cancer Research. Invited. Washington, DC, US.
2006. The NCI's Translational Research Working Group - Status Report. Invited. Bethesda, MD, US.
2005. The Future of Translational Science in Cancer. Invited. Bethesda, MD, US.
2004. Esophageal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
2003. State of the Science in Clinical Cancer Prevention. Invited. Bethesda, MD, US.
2003. Colorectal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
2002. DCP Drug Development Program. Invited. Bethesda, MD, US.
2002. Colorectal Cancer Chemoprevention. Invited. Bethesda, MD, US.
2002. COX-2 as a Molecular Target for Prevention. Invited. Bethesda, MD, US.
2002. Colorectal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
2002. Phase II Prevention Trials - The Translational Bridge Between Prevention Science and Clinical Benefits. Invited. Bethesda, MD, US.
2001. NSAIDs and Cancer Prevention - NCI's Portfolio. Invited. Bethesda, MD, US.
2001. Research Gaps, Needs, and Opportunities in Barrett's Esophagus. Invited. Bethesda, MD, US.
2001. Intermediate Biomarkers - Uses, Advantages, and Disadvantages as Markers of Preventive Efficacy. Invited. Bethesda, MD, US.
2001. Putting Prevention into Practice - Now and In the Future. Invited. Bethesda, MD, US.
2001. Colorectal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
2001. Prevention and Therapeutic Interventions in Esophageal Carcinogenesis. Invited. Bethesda, MD, US.
2000. NCI's Research Portfolio in Barrett's Esophageal Cancer - Etiology, Early Detection, Prevention, and Treatment. Invited, US.
2000. Esophageal Cancer - Epidemiology & Prevention. Invited. Bethesda, MD, US.
1998. Molecular and Cellular Carcinogenesis - The Process as a Disease. Invited. Bethesda, MD, US.
1997. Molecular and Cellular Carcinogenesis - The Process as a Disease. Invited. Bethesda, MD, US.

Less

Grant & Contract Support

Date:	2024 - 2027
Title:	Project 80% Colorectal Cancer Screening Program
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Consult
ID:	PP250005

Date:	2022 - 2025
Title:	Project ACCESS: Increasing Access to Cervical Cancer Screening & Treatment Services in Texas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	PP220037

Date:	2020 - 2022
Title:	Advances in our understanding of the mechanisms of obesity and radiation in carcinogenesis, and personalized cancer etiology
Funding Source:	John Templeton Foundation
Role:	Co-I
ID:	61471

Date:	2020 - 2021
Title:	Be Well Communities(TM): A Model for Cancer Prevention & Control in Underserved Communities
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	3P30CA016672-44S5

Date:	2020 - 2021
Title:	HPV vaccine hesitancy and uptake within The University of Texas System - A catalyst for population-level advances
Funding Source:	NIH/NCI
Role:	Project Leader

Date:	2020 - 2021
Title:	Cannabis use among cancer patients and survivors: access, use patterns, knowledge, perceived risks and benefits; and interactions with healthcare providers
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2019 - 2024
Title:	Project 3: Non-Invasive Assessment of Liver Fibrosis Stage and Progression in Obesity and Diabetes: A Hispanic Population Study
Funding Source:	NIH/NCI
Role:	Co-I
ID:	P50CA217674-01A

Date:	2019 - 2024
Title:	Core Infrastructure Support
Funding Source:	NIH/NCI
Role:	Co-I
ID:	HHSN261201200034I / 75N91019F00129

Date:	2019 - 2024
Title:	Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RFA R-19.2-CAP:CAC

Date:	2019 - 2022
Title:	Expansion of cervical cancer prevention services to medically underserved populations through patient outreach, navigation & provider training/telementoring
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Program Director
ID:	PP190014

Date:	2017 - 2021
Title:	INCan Collaborative Development of a Curriculum in Cancer Prevention and Control for the Institute Nacional de Cancerologia in Mexico
Funding Source:	CRDF Global
Role:	PI
ID:	59-0210-6-004

Date:	2017 - 2022
Title:	The Role of Methyl Donors in Cancer Risk
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA219983

Date:	2017 - 2019
Title:	Aspirin-PC for Chemoprevention of Colorectal Cancer
Funding Source:	PLX Pharma
Role:	Co-I
ID:	R42 CA171408-02A1

Date:	2017 - 2022
Title:	Integrative Analysis of Sequencing Data for Adenoma Development
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1-R01-CA216438-01

Date:	2016 - 2018
Title:	Administrative Supplements for NCI-designated Cancer Centers to Support Population Health Assessment in Cancer Center Catchment Areas
Funding Source:	NIH/NCI
Role:	Co-I
ID:	3P30CA016672-41S6

Date:	2015 - 2017
Title:	Molecular Characterization of Aspirin for Colorectal Cancer Treatment and Prevention
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2015 - 2020
Title:	Genome-Wide Association Study in Hepatocellular Carcinoma (GWAS Study)
Funding Source:	NIH/NCI
Role:	Co-Investigator (Year 5)
ID:	1R01CA186566-01A1

Date:	2015 - 2020
Title:	SPORE in Liver Cancer
Funding Source:	NIH/NCI
Role:	Co-Investigator Project 3

Date:	2015 - 2020
Title:	Multi-Ethnic Cancer Survivorship Cohort
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2014 - 2018
Title:	Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley Through Public Outreach, Patient Navigation, and Telementoring
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Program Director
ID:	PP150012

Date:	2014 - 2016
Title:	Discovering New Targets for Chemoprevention in FAP
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	1R03CA176788-01A1

Date:	2013 - 2016
Title:	A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with FAP and Attenuated FAP
Funding Source:	Cancer Prevention Pharmaceuticals
Role:	Co-PI

Date:	2013 - 2018
Title:	Gut microbiome: integrating risk pathways in obesity and colorectal neoplasia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01

Date:	2013 - 2015
Title:	Aspirin-PC for Chemoprevention of Colorectal Cancer
Funding Source:	NIH/NCI
Role:	Consult
ID:	3R41CA171408-01A1S1

Date:	2012 - 2017
Title:	Esophagus SPORE: Biology of Barrett's Esophagus and Adenocarcinoma
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2012 - 2014
Title:	Use of a FIT-Flu Intervention to Increase Colorectal Cancer Screening Rates in the Houston Metropolitan Area
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Program Director
ID:	PP120207

Date:	2012 - 2017
Title:	Creation of the MD Anderson Cancer Patient Cohort (MDACPC)
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2012 - 2017
Title:	MD Anderson SPORE in Hepatocellular Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2012 - 2016
Title:	A web-based Computational Tool for Prediction of Colorectal Cancer Outcomes
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2012 - 2015
Title:	Implementation of CT Colonography in the Harris County Hospital District for the Diagnostic Evaluation of Patients with Positive FOBT/FIT Test Results
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Significant Contributor

Date:	2011 - 2014
Title:	Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP120280

Date:	2011 - 2017
Title:	Enhancing Minority Participants in Clinical Trials (EMPaCT): Phase II
Funding Source:	NIH/NIMH
Role:	Co-PI
ID:	5U24MD006970-06

Date:	2010 - 2011
Title:	Role of microRNA in Colorectal Cancer Clinical Outcome Prediction: a Genome-wide Analysis
Funding Source:	The University of Texas M.D. Anderson Cancer Center
Role:	Co-I
ID:	Multidisciplinary Research Award

Date:	2010 - 2011
Title:	Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis
Funding Source:	The University of Texas M.D. Anderson Cancer Center
Role:	Co-I
ID:	Multidisciplinary Research Award

Date:	2010 - 2012
Title:	Enhancing Minority Participants in Clinical Trials (EMPaCT)
Funding Source:	NIH/NCI
Role:	Co-Director
ID:	1RC2MD004797-01

Date:	2008 - 2024
Title:	Cancer Center Support Grant
Funding Source:	NIH/NCI
Role:	Member, CCSG Senior Leadership/Associate Director Population Sciences; Director Community Outreach and Engagement; Co-Leader GI Program
ID:	5P30CA016672-44

Date:	2008 - 2016
Title:	Cellular and Molecular Mechanisms of Gastrointestinal Cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P01CA130821-06

Title:	Risk Factors of Hepatocellular Carcinoma in the USA
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Comparative Effectiveness Research Project
Funding Source:	AHRQ
Role:	PI

Title:	Therapeutic Prevention for Colon Cancer
Funding Source:	NIH/NCI
Role:	Co-PI

Title:	MicroRNA and clinical outcome of esophageal cancer: a genome-wide analysis of germline genetic variations and somatic molecular alterations
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator

Title:	Development of PC-conjugated Aspirin for Colon Cancer Prevention
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

CV information above last modified May 14, 2025

Ernest Hawk, M.D., M.P.H.

About Dr. Hawk

In the News

Asbestos exposure and cancer: 8 things to know

What are multi-cancer early detection (MCED) tests, and should you get one?

Artificial sweeteners and cancer: 7 things to know

Radon exposure and lung cancer: 11 things to know

How MD Anderson’s Moon Shots Program is working to end cancer through prevention

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Cancer Prevention and Population Sciences Division

Lyda Hill Cancer Prevention Center

Clinical Cancer Prevention Department

Duncan Family Institute for Cancer Prevention and Risk Assessment

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer

Artificial sweeteners and cancer: 7 things to know 